Belmont, MA, United States of America

Sarah E Poplawski

USPTO Granted Patents = 15 


 

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 77(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Sarah E. Poplawski

Introduction

Sarah E. Poplawski is a prominent inventor based in Belmont, MA, known for her significant contributions to the field of cancer treatment through innovative pharmaceutical developments. With a total of 15 patents to her name, she has made remarkable strides in creating targeted therapies that address critical health challenges.

Latest Patents

Among her latest patents, Poplawski has developed FAP-activated proteasome inhibitors for treating solid tumors. This invention includes proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of these inhibitors, and pharmaceutically acceptable salts. The patent also covers related pharmaceutical compositions and methods for using these inhibitors and prodrugs in treating cancer and other cell proliferative diseases. Additionally, she has disclosed in vitro and in vivo methods for quantifying FAP expression in biopsy samples and mammals. Another notable patent involves FAP-activated therapeutic agents, which are prodrugs of cytotoxic anthracyclines, such as doxorubicin. These prodrugs are selectively cleaved and activated by FAP, allowing for targeted delivery to FAP-expressing tissues, including solid tumors. This innovation is crucial for treating disorders characterized by FAP upregulation, such as cancer, fibrosis, and inflammation.

Career Highlights

Throughout her career, Poplawski has worked with notable organizations, including Bach Biosciences, LLC and Tufts College. Her work has significantly impacted the development of targeted cancer therapies, showcasing her dedication to advancing medical science.

Collaborations

Poplawski has collaborated with esteemed colleagues, including William W. Bachovchin and Hung-sen Lai, further enhancing her research and development efforts in the pharmaceutical field.

Conclusion

Sarah E. Poplawski's innovative work in developing targeted cancer therapies through her patents exemplifies her commitment to improving patient outcomes. Her contributions continue to influence the landscape of cancer treatment and pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…